Alva, A. S. Et Al. 2021. Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6 .

Alva, A. S., Csoszi, T., ÖZGÜROĞLU, M., Matsubara, N., Geczi, L., Cheng, S. Y., ... Fradet, Y.(2021). Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

Alva, Ajjai Et Al. "Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

Alva, Ajjai S. Et Al. "Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

Alva, A. S. Et Al. (2021) . "Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

@article{article, author={Ajjai Shivaram Alva Et Al. }, title={Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}